Screener
Theravance Biopharma TBPH Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from the sale of ordinary shares | — | 20 |
| Proceeds from option exercises | 1,378 | — |
| Repurchase of shares to satisfy tax withholding | (7,922) | (1,377) |
| Net cash used in financing activities | (6,544) | (1,357) |
| Net increase in cash, cash equivalents, and restricted cash | 51,960 | 244,130 |
| Cash, cash equivalents, and restricted cash at beginning of period | 168,642 | 38,633 |
| Cash, cash equivalents, and restricted cash at end of period | $220,602 | $282,763 |
| Supplemental disclosure of cash flow information |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's financing cash flow?
- Theravance Biopharma (TBPH) reported financing cash flow of -$967K in Q2 2026.
- How has Theravance Biopharma's financing cash flow changed year-over-year?
- Theravance Biopharma's financing cash flow decreased by 92.2% year-over-year, from -$503K to -$967K.
- What is the long-term trend for Theravance Biopharma's financing cash flow?
- Over 4 years (2021 to 2025), Theravance Biopharma's financing cash flow has grown at a -56.9% compound annual growth rate (CAGR), from $94.15M to -$3.25M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Theravance Biopharma's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude